how big is the glp-1 market Drugs Size to Hit USD 132.79 Bn by 2035 Overview of GLP-1s
Description
Regulatory and Clinical Support : Guidelines recognizing obesity as a chronic disease and broader approval of GLP1 drugs are pushing adoption and reimbursement in healthcare systems
,
Effect of liraglutide 3.0 mg treatment on weight reduction in obese antipsychotic-treated patients
Abstract The glucagon-like peptide-1 receptor (GLP-1R) is a class B G protein-coupled receptor and mainstay therapeutic target for the treatment of type 2 diabetes and obesity
Short-acting GLP1s cause more nausea
GLP-1s are neither universally good nor bad for IBS
